Nanovalent Pharmaceuticals has developed a unique platform technology known as Targeted Nanosphere (TNS), which aims to enhance the delivery, safety, and efficacy of cancer therapeutics, including antibody-drug conjugates (ADCs). This innovative approach is exemplified by their lead product, NV103, which is nearing Investigational New Drug (IND) status and is expected to enter clinical trials in 2026. The TNS platform is designed to be highly flexible, allowing for the development of various product candidates that can significantly improve upon existing treatment modalities. The company collaborates closely with Children’s Hospital Los Angeles and other academic partners, leveraging their expertise to advance their therapeutic offerings.

The TNS technology focuses on targeted delivery mechanisms that can potentially overcome the limitations of traditional cancer therapies. By utilizing engineered nanoparticles, Nanovalent aims to achieve more precise targeting of cancer cells, thereby minimizing side effects and enhancing therapeutic outcomes. The company’s pipeline includes a range of products that are in various stages of development, reflecting their commitment to addressing unmet medical needs in oncology. With a strong management team and a focus on innovative research, Nanovalent Pharmaceuticals is positioned to make significant contributions to the field of cancer treatment through its advanced nanotechnology platforms.

United States

NanoValent Pharmaceuticals, Inc. is a pharmaceutical company developing a new nano-particle based TNS (Targeted NanoSpheres) technology to create and develop novel cancer therapies

Nanovalent Pharmaceuticals

Company Details